Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Host targeted antiviral (HTA): functional inhibitor compounds of scaffold protein RACK1 inhibit herpes simplex virus proliferation.

Ullah H, Hou W, Dakshanamurthy S, Tang Q.

Oncotarget. 2019 May 14;10(35):3209-3226. doi: 10.18632/oncotarget.26907. eCollection 2019 May 14.

2.

Differential prioritization of therapies to subtypes of triple negative breast cancer using a systems medicine method.

Wathieu H, Issa NT, Fernandez AI, Mohandoss M, Tiek DM, Franke JL, Byers SW, Riggins RB, Dakshanamurthy S.

Oncotarget. 2017 Oct 9;8(54):92926-92942. doi: 10.18632/oncotarget.21669. eCollection 2017 Nov 3.

3.

Drug Metabolism in Preclinical Drug Development: A Survey of the Discovery Process, Toxicology, and Computational Tools.

Issa NT, Wathieu H, Ojo A, Byers SW, Dakshanamurthy S.

Curr Drug Metab. 2017;18(6):556-565. doi: 10.2174/1389200218666170316093301. Review.

4.

The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma.

Simbulan-Rosenthal CM, Dakshanamurthy S, Gaur A, Chen YS, Fang HB, Abdussamad M, Zhou H, Zapas J, Calvert V, Petricoin EF, Atkins MB, Byers SW, Rosenthal DS.

Oncotarget. 2017 Feb 21;8(8):12576-12595. doi: 10.18632/oncotarget.14990.

5.

MSD-MAP: A Network-Based Systems Biology Platform for Predicting Disease-Metabolite Links.

Wathieu H, Issa NT, Mohandoss M, Byers SW, Dakshanamurthy S.

Comb Chem High Throughput Screen. 2017;20(3):193-207. doi: 10.2174/1386207319666161214111254.

PMID:
28024464
6.

Prediction of Chemical Multi-target Profiles and Adverse Outcomes with Systems Toxicology.

Wathieu H, Ojo A, Dakshanamurthy S.

Curr Med Chem. 2017;24(16):1705-1720. doi: 10.2174/0929867323666161214115540. Review.

PMID:
27978797
7.

DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-based drug repurposing.

Issa NT, Kruger J, Wathieu H, Raja R, Byers SW, Dakshanamurthy S.

BMC Bioinformatics. 2016 May 5;17(1):202. doi: 10.1186/s12859-016-1065-y.

8.

Harnessing Polypharmacology with Computer-Aided Drug Design and Systems Biology.

Wathieu H, Issa NT, Byers SW, Dakshanamurthy S.

Curr Pharm Des. 2016;22(21):3097-108. Review.

PMID:
26907947
9.

RepurposeVS: A Drug Repurposing-Focused Computational Method for Accurate Drug-Target Signature Predictions.

Issa NT, Peters OJ, Byers SW, Dakshanamurthy S.

Comb Chem High Throughput Screen. 2015;18(8):784-94.

10.

Naturally occurring polyphenol, morin hydrate, inhibits enzymatic activity of N-methylpurine DNA glycosylase, a DNA repair enzyme with various roles in human disease.

Dixon M, Woodrick J, Gupta S, Karmahapatra SK, Devito S, Vasudevan S, Dakshanamurthy S, Adhikari S, Yenugonda VM, Roy R.

Bioorg Med Chem. 2015 Mar 1;23(5):1102-11. doi: 10.1016/j.bmc.2014.12.067. Epub 2015 Jan 17. Erratum in: Bioorg Med Chem. 2015 Aug 1;23(15):5077.

11.

Germ line variants of human N-methylpurine DNA glycosylase show impaired DNA repair activity and facilitate 1,N6-ethenoadenine-induced mutations.

Adhikari S, Chetram MA, Woodrick J, Mitra PS, Manthena PV, Khatkar P, Dakshanamurthy S, Dixon M, Karmahapatra SK, Nuthalapati NK, Gupta S, Narasimhan G, Mazumder R, Loffredo CA, Üren A, Roy R.

J Biol Chem. 2015 Feb 20;290(8):4966-80. doi: 10.1074/jbc.M114.627000. Epub 2014 Dec 23.

12.

A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors.

Petrini I, Meltzer PS, Kim IK, Lucchi M, Park KS, Fontanini G, Gao J, Zucali PA, Calabrese F, Favaretto A, Rea F, Rodriguez-Canales J, Walker RL, Pineda M, Zhu YJ, Lau C, Killian KJ, Bilke S, Voeller D, Dakshanamurthy S, Wang Y, Giaccone G.

Nat Genet. 2014 Aug;46(8):844-9. doi: 10.1038/ng.3016. Epub 2014 Jun 29.

13.

Accelerating Virtual High-Throughput Ligand Docking: current technology and case study on a petascale supercomputer.

Ellingson SR, Dakshanamurthy S, Brown M, Smith JC, Baudry J.

Concurr Comput. 2014 Apr 25;26(6):1268-1277.

14.

Big data: the next frontier for innovation in therapeutics and healthcare.

Issa NT, Byers SW, Dakshanamurthy S.

Expert Rev Clin Pharmacol. 2014 May;7(3):293-8. doi: 10.1586/17512433.2014.905201. Epub 2014 Apr 7. Review.

15.

Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies.

Assefnia S, Dakshanamurthy S, Guidry Auvil JM, Hampel C, Anastasiadis PZ, Kallakury B, Uren A, Foley DW, Brown ML, Shapiro L, Brenner M, Haigh D, Byers SW.

Oncotarget. 2014 Mar 30;5(6):1458-74.

16.

Allelic variation of killer cell immunoglobulin-like receptor 2DS5 impacts glycosylation altering cell surface expression levels.

Steiner NK, Dakshanamurthy S, Nguyen N, Hurley CK.

Hum Immunol. 2014 Feb;75(2):124-8. doi: 10.1016/j.humimm.2013.11.012. Epub 2013 Nov 20.

17.

Drug repurposing: translational pharmacology, chemistry, computers and the clinic.

Issa NT, Byers SW, Dakshanamurthy S.

Curr Top Med Chem. 2013;13(18):2328-36. Review.

PMID:
24059462
18.

Design, synthesis and discovery of picomolar selective α4β2 nicotinic acetylcholine receptor ligands.

Yenugonda VM, Xiao Y, Levin ED, Rezvani AH, Tran T, Al-Muhtasib N, Sahibzada N, Xie T, Wells C, Slade S, Johnson JE, Dakshanamurthy S, Kong HS, Tomita Y, Liu Y, Paige M, Kellar KJ, Brown ML.

J Med Chem. 2013 Nov 14;56(21):8404-21. doi: 10.1021/jm4008455. Epub 2013 Oct 18.

PMID:
24047231
19.

Allelic variation in KIR2DL3 generates a KIR2DL2-like receptor with increased binding to its HLA-C ligand.

Frazier WR, Steiner N, Hou L, Dakshanamurthy S, Hurley CK.

J Immunol. 2013 Jun 15;190(12):6198-208. doi: 10.4049/jimmunol.1300464. Epub 2013 May 17.

20.

Drug repurposing a reality: from computers to the clinic.

Issa NT, Kruger J, Byers SW, Dakshanamurthy S.

Expert Rev Clin Pharmacol. 2013 Mar;6(2):95-7. doi: 10.1586/ecp.12.79. No abstract available.

21.

Synthesis and biological evaluation of a fluorescent analog of phenytoin as a potential inhibitor of neuropathic pain and imaging agent.

Walls TH, Grindrod SC, Beraud D, Zhang L, Baheti AR, Dakshanamurthy S, Patel MK, Brown ML, MacArthur LH.

Bioorg Med Chem. 2012 Sep 1;20(17):5269-76. doi: 10.1016/j.bmc.2012.06.042. Epub 2012 Jul 3.

22.

Predicting new indications for approved drugs using a proteochemometric method.

Dakshanamurthy S, Issa NT, Assefnia S, Seshasayee A, Peters OJ, Madhavan S, Uren A, Brown ML, Byers SW.

J Med Chem. 2012 Aug 9;55(15):6832-48. doi: 10.1021/jm300576q. Epub 2012 Jul 25.

23.

Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK).

Shajahan AN, Dobbin ZC, Hickman FE, Dakshanamurthy S, Clarke R.

J Biol Chem. 2012 May 18;287(21):17682-92. doi: 10.1074/jbc.M111.304022. Epub 2012 Mar 20.

24.

Mechanisms of unphosphorylated STAT3 transcription factor binding to DNA.

Timofeeva OA, Chasovskikh S, Lonskaya I, Tarasova NI, Khavrutskii L, Tarasov SG, Zhang X, Korostyshevskiy VR, Cheema A, Zhang L, Dakshanamurthy S, Brown ML, Dritschilo A.

J Biol Chem. 2012 Apr 20;287(17):14192-200. doi: 10.1074/jbc.M111.323899. Epub 2012 Feb 29.

25.

Asymmetric synthesis and evaluation of a hydroxyphenylamide voltage-gated sodium channel blocker in human prostate cancer xenografts.

Davis GC, Kong Y, Paige M, Li Z, Merrick EC, Hansen T, Suy S, Wang K, Dakshanamurthy S, Cordova A, McManus OB, Williams BS, Chruszcz M, Minor W, Patel MK, Brown ML.

Bioorg Med Chem. 2012 Mar 15;20(6):2180-8. doi: 10.1016/j.bmc.2011.08.061. Epub 2011 Sep 1.

26.

Polygamain, a new microtubule depolymerizing agent that occupies a unique pharmacophore in the colchicine site.

Hartley RM, Peng J, Fest GA, Dakshanamurthy S, Frantz DE, Brown ML, Mooberry SL.

Mol Pharmacol. 2012 Mar;81(3):431-9. doi: 10.1124/mol.111.075838. Epub 2011 Dec 14.

27.

G-DOC: a systems medicine platform for personalized oncology.

Madhavan S, Gusev Y, Harris M, Tanenbaum DM, Gauba R, Bhuvaneshwar K, Shinohara A, Rosso K, Carabet LA, Song L, Riggins RB, Dakshanamurthy S, Wang Y, Byers SW, Clarke R, Weiner LM.

Neoplasia. 2011 Sep;13(9):771-83.

28.

Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells.

Bulut G, Hong SH, Chen K, Beauchamp EM, Rahim S, Kosturko GW, Glasgow E, Dakshanamurthy S, Lee HS, Daar I, Toretsky JA, Khanna C, Uren A.

Oncogene. 2012 Jan 19;31(3):269-81. doi: 10.1038/onc.2011.245. Epub 2011 Jun 27.

29.

Histone deacetylase cytoplasmic trapping by a novel fluorescent HDAC inhibitor.

Kong Y, Jung M, Wang K, Grindrod S, Velena A, Lee SA, Dakshanamurthy S, Yang Y, Miessau M, Zheng C, Dritschilo A, Brown ML.

Mol Cancer Ther. 2011 Sep;10(9):1591-9. doi: 10.1158/1535-7163.MCT-10-0779. Epub 2011 Jun 22.

30.

Synthesis and evaluation of hermitamides A and B as human voltage-gated sodium channel blockers.

De Oliveira EO, Graf KM, Patel MK, Baheti A, Kong HS, MacArthur LH, Dakshanamurthy S, Wang K, Brown ML, Paige M.

Bioorg Med Chem. 2011 Jul 15;19(14):4322-9. doi: 10.1016/j.bmc.2011.05.043. Epub 2011 May 30.

31.

Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells.

Yenugonda VM, Deb TB, Grindrod SC, Dakshanamurthy S, Yang Y, Paige M, Brown ML.

Bioorg Med Chem. 2011 Apr 15;19(8):2714-25. doi: 10.1016/j.bmc.2011.02.052. Epub 2011 Mar 4.

PMID:
21440449
32.

Tumor suppressor RARRES1 interacts with cytoplasmic carboxypeptidase AGBL2 to regulate the α-tubulin tyrosination cycle.

Sahab ZJ, Hall MD, Me Sung Y, Dakshanamurthy S, Ji Y, Kumar D, Byers SW.

Cancer Res. 2011 Feb 15;71(4):1219-28. doi: 10.1158/0008-5472.CAN-10-2294. Epub 2011 Feb 8.

33.

The role of calcium in the activation of estrogen receptor-alpha.

Divekar SD, Storchan GB, Sperle K, Veselik DJ, Johnson E, Dakshanamurthy S, Lajiminmuhip YN, Nakles RE, Huang L, Martin MB.

Cancer Res. 2011 Mar 1;71(5):1658-68. doi: 10.1158/0008-5472.CAN-10-1899. Epub 2011 Jan 6.

34.

Functional mimicry of the acetylated C-terminal tail of p53 by a SUMO-1 acetylated domain, SAD.

Cheema A, Knights CD, Rao M, Catania J, Perez R, Simons B, Dakshanamurthy S, Kolukula VK, Tilli M, Furth PA, Albanese C, Avantaggiati ML.

J Cell Physiol. 2010 Nov;225(2):371-84. doi: 10.1002/jcp.22224.

35.

ApoE mimetic peptide decreases Abeta production in vitro and in vivo.

Minami SS, Cordova A, Cirrito JR, Tesoriero JA, Babus LW, Davis GC, Dakshanamurthy S, Turner RS, Pak DTs, Rebeck GW, Paige M, Hoe HS.

Mol Neurodegener. 2010 Apr 20;5:16. doi: 10.1186/1750-1326-5-16.

36.

Retinoic acid mediates regulation of network formation by COUP-TFII and VE-cadherin expression by TGFbeta receptor kinase in breast cancer cells.

Prahalad P, Dakshanamurthy S, Ressom H, Byers SW.

PLoS One. 2010 Apr 6;5(4):e10023. doi: 10.1371/journal.pone.0010023.

37.

Quinolinol and peptide inhibitors of zinc protease in botulinum neurotoxin A: effects of zinc ion and peptides on inhibition.

Lai H, Feng M, Roxas-Duncan V, Dakshanamurthy S, Smith LA, Yang DC.

Arch Biochem Biophys. 2009 Nov;491(1-2):75-84. doi: 10.1016/j.abb.2009.09.008. Epub 2009 Sep 20.

PMID:
19772855
38.

A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma.

Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, Yuan L, Abaan OD, Chou TH, Dakshanamurthy S, Brown ML, Uren A, Toretsky JA.

Nat Med. 2009 Jul;15(7):750-6. doi: 10.1038/nm.1983. Epub 2009 Jul 5.

39.

Evaluating the potential impact of mismatches outside the antigen recognition site in unrelated hematopoietic stem cell transplantation: HLA-DRB1*1454 and DRB1*140101.

Xiao Y, Lazaro AM, Masaberg C, Haagenson M, Vierra-Green C, Spellman S, Dakshanamurthy S, Ng J, Hurley CK.

Tissue Antigens. 2009 Jun;73(6):595-8. doi: 10.1111/j.1399-0039.2009.01245.x. Epub 2009 Apr 6.

40.

Cancer preventive isothiocyanates induce selective degradation of cellular alpha- and beta-tubulins by proteasomes.

Mi L, Gan N, Cheema A, Dakshanamurthy S, Wang X, Yang DC, Chung FL.

J Biol Chem. 2009 Jun 19;284(25):17039-51. doi: 10.1074/jbc.M901789200. Epub 2009 Apr 1.

41.

Inhibition of cell proliferation by a resveratrol analog in human pancreatic and breast cancer cells.

Hong YB, Kang HJ, Kim HJ, Rosen EM, Dakshanamurthy S, Rondanin R, Baruchello R, Grisolia G, Daniele S, Bae I.

Exp Mol Med. 2009 Mar 31;41(3):151-60. doi: 10.3858/emm.2009.41.3.018.

42.

Dramatically reduced surface expression of NK cell receptor KIR2DS3 is attributed to multiple residues throughout the molecule.

VandenBussche CJ, Mulrooney TJ, Frazier WR, Dakshanamurthy S, Hurley CK.

Genes Immun. 2009 Mar;10(2):162-73. doi: 10.1038/gene.2008.91. Epub 2008 Nov 13.

43.

Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells.

Oh AS, Lahusen JT, Chien CD, Fereshteh MP, Zhang X, Dakshanamurthy S, Xu J, Kagan BL, Wellstein A, Riegel AT.

Mol Cell Biol. 2008 Nov;28(21):6580-93. doi: 10.1128/MCB.00118-08. Epub 2008 Sep 2.

44.

Extracellular domain alterations impact surface expression of stimulatory natural killer cell receptor KIR2DS5.

Steiner NK, Dakshanamurthy S, VandenBussche CJ, Hurley CK.

Immunogenetics. 2008 Nov;60(11):655-67. doi: 10.1007/s00251-008-0322-2. Epub 2008 Aug 6.

45.

Asymmetric synthesis of 2,3-dihydro-2-arylquinazolin-4-ones: methodology and application to a potent fluorescent tubulin inhibitor with anticancer activity.

Chinigo GM, Paige M, Grindrod S, Hamel E, Dakshanamurthy S, Chruszcz M, Minor W, Brown ML.

J Med Chem. 2008 Aug 14;51(15):4620-31. doi: 10.1021/jm800271c. Epub 2008 Jul 9.

46.

Covalent binding to tubulin by isothiocyanates. A mechanism of cell growth arrest and apoptosis.

Mi L, Xiao Z, Hood BL, Dakshanamurthy S, Wang X, Govind S, Conrads TP, Veenstra TD, Chung FL.

J Biol Chem. 2008 Aug 8;283(32):22136-46. doi: 10.1074/jbc.M802330200. Epub 2008 Jun 3.

47.

Activation of estrogen receptor-alpha by the anion nitrite.

Veselik DJ, Divekar S, Dakshanamurthy S, Storchan GB, Turner JM, Graham KL, Huang L, Stoica A, Martin MB.

Cancer Res. 2008 May 15;68(10):3950-8. doi: 10.1158/0008-5472.CAN-07-2783.

48.

In-silico fragment-based identification of novel angiogenesis inhibitors.

Dakshanamurthy S, Kim M, Brown ML, Byers SW.

Bioorg Med Chem Lett. 2007 Aug 15;17(16):4551-6. Epub 2007 Jun 15.

PMID:
17591441
49.

Identification and characterization of a new tubulin-binding tetrasubstituted brominated pyrrole.

Mooberry SL, Weiderhold KN, Dakshanamurthy S, Hamel E, Banner EJ, Kharlamova A, Hempel J, Gupton JT, Brown ML.

Mol Pharmacol. 2007 Jul;72(1):132-40. Epub 2007 Apr 24.

PMID:
17456786
50.

A single polymorphism disrupts the killer Ig-like receptor 2DL2/2DL3 D1 domain.

VandenBussche CJ, Dakshanamurthy S, Posch PE, Hurley CK.

J Immunol. 2006 Oct 15;177(8):5347-57.

Supplemental Content

Loading ...
Support Center